BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quest Pharmaceutical Services Announces New Molecular Biology Services At American Association of Pharmaceutical Scientists, American Diabetes Association


6/19/2006 11:35:20 AM

NEWARK, Del., June 19 /PRNewswire/ -- Quest Pharmaceutical Services (QPS), a full-service, GLP-compliant, contract research organization, is announcing the launch of its new Molecular Biology Service during two major meetings this week - the American Association of Pharmaceutical Scientists' National Biotechnology Conference in Boston (Booth #521) and the annual meeting of the Drug Information Association in Philadelphia (Booth #814).

"This new service will provide our pharmaceutical and biotech customers with top quality data to help assess drug toxicity and drug response necessary for patient stratification, treatment decision making, and therapy evaluation in drug development," says Dr. Ben Chien, President and CEO of the privately held, Delaware-based firm.

The new QPS department, located at its Newark facility, has assembled best-in-class instrumentations, platforms, and processes required to conduct studies supporting client drug discovery and development strategies. It offers a wide variety of services for integration of pharmacogenomics (PGx) into drug development, including automated RNA and DNA isolation, genotyping and genetic mutation analysis, gene expression profiling analysis, quantitative determination of CpG methylation, viral load determination, and custom assays.

"Our mission is to provide PGx technologies to help drug sponsors develop therapeutics with better efficacy and safety profiles," says Dr. Ling Sing Chen, Executive Director of Molecular Biology at QPS. "This in turn will shorten drug development timelines and reduce development costs."

More information can be accessed at http://www.questpharm.com/molecular.htm.

Founded in 1995, QPS has DMPK facilities in Newark and in Taipei, Taiwan, and partners worldwide with drug researchers to provide services in ADME, in-vivo/in-vitro drug metabolism, PK, protein binding, whole body autoradiography, LC/MS/MS quantitation, molecular biology, immunology, and biomarkers. It has a capacity of 39 triple quadrupoles mass spectrometers and a fully validated Watson LIMS system for data handling and report writing.

Quest Pharmaceutical Services

CONTACT: Roger Morris, The LondonBritain Company, +1-610-274-8027,londonbritain@msn.com, for Quest Pharmaceutical Services



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES